Home Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers
Article
Licensed
Unlicensed Requires Authentication

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers

  • Elad Sharon , Jingli Zhang , Kevin Hollevoet , Seth M. Steinberg , Ira Pastan , Masanori Onda , Jochen Gaedcke , B. Michael Ghadimi , Thomas Ried and Raffit Hassan EMAIL logo
Published/Copyright: December 8, 2011
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine
From the journal Clinical Chemistry and Laboratory Medicine Volume 50 Issue 4

Abstract

Background: Tumor mesothelin overexpression is present in different malignancies, including the majority of patients with pancreatic or biliary cancers. The objective of this study was to evaluate the use of shed serum mesothelin and megakaryocyte potentiating factor (MPF) concentrations as biomarkers for these cancers.

Methods: A total of 151 individuals, divided into five groups, were retrospectively analyzed: healthy donors (n=15), patients with benign non-pancreatic conditions (n=52), benign pancreatic conditions (n=33), biliary carcinoma (n=9), and pancreatic ductal adenocarcinoma (n=42). Mesothelin and MPF concentrations were measured in serum with the Mesomark™ and Human MPF ELISA, respectively.

Results: Mesothelin and MPF concentrations did not significantly differ among the five individual participant groups (p=0.34, p=0.33, respectively), nor did any other combination and pair-wise comparison of the participant groups demonstrated a significant difference in biomarker concentrations. In patients with pancreatic cancer, mesothelin or MPF concentrations were not associated with tumor stage (p=0.87, p=0.48, respectively) or differentiation grade (p=0.73, p=0.52, respectively).

Conclusions: Serum mesothelin and MPF concentrations, measured with standard available ELISAs, were not specific for benign or pancreatic disease. Both biomarkers were not elevated in patients with pancreatic or biliary cancers, and consequently do not appear to be useful biomarkers for these malignancies.

Keywords: biliary cancer; megakaryocyte potentiating factor; mesothelin; pancreatic cancer
Corresponding author: Raffit Hassan, Laboratory of Molecular Biology, NCI, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264, USA Phone: +1 301 451-8742, Fax: +1 301 402-1344
Received: 2011-10-7
Accepted: 2011-11-14
Published Online: 2011-12-08
Published in Print: 2012-04-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. A sensitive quantitative test strip based point-of-care albuminuria screening assay
  2. Editorials
  3. Serum biomarkers for the non-invasive diagnosis of liver fibrosis: the importance of being validated
  4. Primary blood tubes mixing: time for updated recommendations
  5. Reviews
  6. 10.1515/cclm-2011-0847
  7. The hCG assay or pregnancy test
  8. Mini Reviews
  9. The role of mean platelet volume in predicting thrombotic events
  10. The role of red blood cell distribution width in cardiovascular and thrombotic disorders
  11. Genetics and Molecular Diagnostics
  12. Comparison of different collection procedures and two methods for DNA isolation from saliva
  13. Detection of α-globin gene deletion and duplication using quantitative multiplex PCR of short fluorescent fragments
  14. High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR
  15. General Clinical Chemistry and Laboratory Medicine
  16. Quantification of human serum insulin concentrations in clinical pharmacokinetic or bioequivalence studies: what defines the “best method”?
  17. Serum cystatin C is an early biomarker for assessment of renal function in burn patients
  18. 10.1515/cclm.2011.0849
  19. Mid-stream vs. first-voided urine collection by using automated analyzers for particle examination in healthy subjects: an Italian multicenter study
  20. Percentage of hypochromic erythrocytes as a potential marker of iron availability
  21. Laboratory evaluation of a flow cytometric BCR-ABL immunobead assay
  22. Validation and Outcome Studies
  23. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C
  24. Cancer Diagnostics
  25. Demasking of epithelial cell adhesion molecule (EpCAM) on circulating epithelial tumor cells by Tween®20 treatment in breast cancer patients
  26. Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer
  27. Blood presence of circulating oncofetal fibronectin mRNA, by RT-PCR, does not represent a useful specific marker for the management and follow-up of thyroid cancer patients
  28. Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers
  29. Cardiovascular Diseases
  30. The performance of high sensitivity troponin for the diagnosis of acute myocardial infarction is underestimated
  31. The prognostic value of N-terminal pro-brain natriuretic peptide in non-ST elevation acute coronary syndromes: a meta-analysis
  32. Measurement of high-molecular-weight adiponectin is not useful in assessing coronary stenosis
  33. Letters to the Editor
  34. Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I
  35. Evaluation of the interference by homogentisic acid and other organic acids on the enzymatic and Jaffé method creatinine assay
  36. A comparative analysis of the Iris iQ200 with manual microscopy as a diagnostic tool for dysmorphic erythrocytes in urine
  37. Falsely decreased ionized calcium results due to analytical interference by teriflunomide, the active metabolite of leflunomide (Arava®)
  38. Is polyethylene glycol precipitation of hyperprolactinaemic samples required when using the Beckman Coulter DxI-800 prolactin assay?
  39. Congress Abstracts
  40. ISMD2012: Ninth International Symposium on Molecular Diagnostics
  41. ArabMedLab Marrakech 2012
  42. Masthead
  43. Masthead
https://doi.org/10.1515/cclm.2011.816
Keywords for this article
biliary cancer; megakaryocyte potentiating factor; mesothelin; pancreatic cancer

Articles in the same Issue

  1. A sensitive quantitative test strip based point-of-care albuminuria screening assay
  2. Editorials
  3. Serum biomarkers for the non-invasive diagnosis of liver fibrosis: the importance of being validated
  4. Primary blood tubes mixing: time for updated recommendations
  5. Reviews
  6. 10.1515/cclm-2011-0847
  7. The hCG assay or pregnancy test
  8. Mini Reviews
  9. The role of mean platelet volume in predicting thrombotic events
  10. The role of red blood cell distribution width in cardiovascular and thrombotic disorders
  11. Genetics and Molecular Diagnostics
  12. Comparison of different collection procedures and two methods for DNA isolation from saliva
  13. Detection of α-globin gene deletion and duplication using quantitative multiplex PCR of short fluorescent fragments
  14. High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR
  15. General Clinical Chemistry and Laboratory Medicine
  16. Quantification of human serum insulin concentrations in clinical pharmacokinetic or bioequivalence studies: what defines the “best method”?
  17. Serum cystatin C is an early biomarker for assessment of renal function in burn patients
  18. 10.1515/cclm.2011.0849
  19. Mid-stream vs. first-voided urine collection by using automated analyzers for particle examination in healthy subjects: an Italian multicenter study
  20. Percentage of hypochromic erythrocytes as a potential marker of iron availability
  21. Laboratory evaluation of a flow cytometric BCR-ABL immunobead assay
  22. Validation and Outcome Studies
  23. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C
  24. Cancer Diagnostics
  25. Demasking of epithelial cell adhesion molecule (EpCAM) on circulating epithelial tumor cells by Tween®20 treatment in breast cancer patients
  26. Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer
  27. Blood presence of circulating oncofetal fibronectin mRNA, by RT-PCR, does not represent a useful specific marker for the management and follow-up of thyroid cancer patients
  28. Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers
  29. Cardiovascular Diseases
  30. The performance of high sensitivity troponin for the diagnosis of acute myocardial infarction is underestimated
  31. The prognostic value of N-terminal pro-brain natriuretic peptide in non-ST elevation acute coronary syndromes: a meta-analysis
  32. Measurement of high-molecular-weight adiponectin is not useful in assessing coronary stenosis
  33. Letters to the Editor
  34. Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I
  35. Evaluation of the interference by homogentisic acid and other organic acids on the enzymatic and Jaffé method creatinine assay
  36. A comparative analysis of the Iris iQ200 with manual microscopy as a diagnostic tool for dysmorphic erythrocytes in urine
  37. Falsely decreased ionized calcium results due to analytical interference by teriflunomide, the active metabolite of leflunomide (Arava®)
  38. Is polyethylene glycol precipitation of hyperprolactinaemic samples required when using the Beckman Coulter DxI-800 prolactin assay?
  39. Congress Abstracts
  40. ISMD2012: Ninth International Symposium on Molecular Diagnostics
  41. ArabMedLab Marrakech 2012
  42. Masthead
  43. Masthead
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 8.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm.2011.816/html
Scroll to top button